ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

BIVI BioVie Inc

0.5286
-0.005 (-0.94%)
Mar 28 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 778,922
Bid Price 0.5015
Ask Price 0.55
News -
Day High 0.5448

Low
0.4812

52 Week Range

High
8.9699

Day Low 0.51
Company Name Stock Ticker Symbol Market Type
BioVie Inc BIVI NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.005 -0.94% 0.5286 20:00:00
Open Price Low Price High Price Close Price Prev Close
0.5336 0.51 0.5448 0.5286 0.5336
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
2,202 778,922 $ 0.5318769 $ 414,291 - 0.4812 - 8.9699
Last Trade Time Type Quantity Stock Price Currency
19:54:41 formt 3,850 $ 0.5286 USD

BioVie Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
21.13M 39.87M - 0 -50.26M -1.26 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

BioVie News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No BIVI Message Board. Create One! See More Posts on BIVI Message Board See More Message Board Posts

Historical BIVI Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.62550.62550.48120.55233791,381,769-0.0969-15.49%
1 Month1.263.310.48121.517,137,999-0.7314-58.05%
3 Months1.333.310.48121.492,598,717-0.8014-60.26%
6 Months3.135.820.48121.821,609,814-2.60-83.11%
1 Year8.558.96990.48122.24920,869-8.02-93.82%
3 Years18.4423.860.48124.00489,353-17.91-97.13%
5 Years10.5046.09770.48124.48426,821-9.97-94.97%

BioVie Description

BioVie Inc is a company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is currently focused on developing and commercializing BIV201, a novel investigational approach to the treatment of ascites due to chronic liver cirrhosis. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

Your Recent History

Delayed Upgrade Clock